BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life
Executive Summary
Bristol-Myers Squibb's proposed $535 mil. payment to settle BuSpar antitrust litigation amounts to more than twice the sales of the anxiety drug during the four months of extended exclusivity for the product that prompted the suits
You may also be interested in...
Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits
Mylan and Aventis are ending the Zagam marketing deal under a settlement of claims arising from supply problems with the antibiotic
Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits
Mylan and Aventis are ending the Zagam marketing deal under a settlement of claims arising from supply problems with the antibiotic
Bristol/FTC Settlement Brings PTO Standards Into Spotlight
The Federal Trade Commission's antitrust settlement with Bristol-Myers Squibb may bring Patent & Trademark Office standards for pharmaceutical patents into the spotlight